Single perivascular delivery of mitomycin C stimulates p21 expression and inhibits neointima formation in rat arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 11, 2005, Pages 2343-2348

  Granada, Juan F ^a   Ensenat, Diana ^b   Keswani, Amit N ^b   Kaluza, Grzegorz L ^a   Raizner, Albert E ^a   Liu, Xiao Ming ^b   Peyton, Kelly J ^b   Azam, Mohammed A ^b   Wang, Hong ^b   Durante, William ^b,c  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angioplasty; Arteries; Mitomycin C; Restenosis; Smooth muscle cells

Indexed keywords

CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; MITOMYCIN C; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; APOPTOSIS; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON; CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA DAMAGE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; ENZYME ACTIVATION; GROWTH INHIBITION; NONHUMAN; PERIVASCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; RESTENOSIS; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AORTA, THORACIC; AORTIC DISEASES; CELL DIVISION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; MITOMYCIN; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TUNICA INTIMA;

EID: 27644461772     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000184779.01822.9d     Document Type: Article

References (39)

1. Orford JL, Selwyn AP, Ganz P, Popma JJ, Rogers C. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000;86: 6H-11H.
2. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, Badimon JJ. Inhibition of intimai thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99: 2164-2170.
3. Dzau VJ, Braun-Dellaeus RC, Shedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249-1256.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
5. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Blinker JA, Raizner AE, Urban P, Heldman AW. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stem: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109:487-493.
6. Wakaki S, Marumo H, Tomioka K, Shimizo G, Kato E, Kamada H, Kudo S, Fujimoto Y. Isolation of new fractions of antitumor mytomycins. Antibiot Chemother. 1958;8:228-240.
7. Bradner WT. Mitomycin C. a clinical update. Cancer Treatment Rev. 2001;27:35-50.
8. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48:314-346.
9. Tahery MM, Lee DA. Review: pharmacologic control of wound healing in glaucoma filtration surgery. J Ocul Pharmacol. 1989;5:155-179.
10. Correa AJ, Reinisch L, Sanders DL, Huang S, Deriso W, Duncavage JA, Garrett CG. Inhibition of subglottic stenosis with mitomycin C in the canine model. Ann Otol Rhinol Laryngol. 1999;108:1053-1060.
11. Durante W, Schini VB, Catovsky S, Kroll MH, Vanhoutte PM, Schafer AI. Plasmin potentiates the induction of nitric oxide synthase by interleukin-1β in vascular. smooth muscle. Am J Physiol Heart Circ Physiol. 1993;264:H617-H623.
12. Peyton KJ,-Reyna SV, Chapman GB, Ensenat D, Liu X, Wang H, Schafer AI, Durante W. Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood. 2002; 99:4443-4448.
13. Liu X, Chapman GB, Peyton KJ, Schafer AI, Durante W. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc Res. 2002;55:396-405.
14. Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun. 2000;279: 649-652.
15. Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, Schafer AI. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001;104: 2710-2715.
16. Fulton GJ, Davies MG, Barber L, Svendsen E, Hagen PO. Locally applied antisense oligonucleotide to proliferating cell nuclear antigen inhibits intimal thickening in experimental vein grafts. Ann Vasc Surg. 1998;12: 412-417.
17. Hu Y, Zou Y, Dietrich H, Wick G, Xu Q. Inhibition of neointima hyperplasia in mouse vein grafts by locally applied suramin. 1999; 100: 861-868.
18. Bohorquez M, Koch T, Trygstad T, Pandit N. A study of the temperature-dependent micellization of Pluronic F127. J Colloid Interface Sci. 1999; 216:34-40.
19. Abe T, Sasaki M, Nakajima H, Ogita M, Naitou H, Nagase A, Taguchi K, Miyazaki S. Evaluation of pluronic F127 as a gradual release of anticancer drug. Gan To Kagaku Ryoho. 1990;17:1546-1550.
20. Nurse P. Universal control mechanisms regulating onset of M-phase. Nature. 1990;344:503-508.
21. Schmittgen TD, Wientjes MG, Badalament RA, Au J. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 1991; 51:3849-3856.
22. Castaneda F, Kinne RK. Effects of doxorubicin, mitomycin C, and ethanol on Hep-G2 cells in vitro. J Cancer Res Clin Oncol. 1999; 125:1-8.
23. Hu D, Sires BS, Tong DC, Royack GA, Oda D. Effect of brief exposure to mitomycin C on cultured human nasal mucosal fibroblasts. Ophthal Plast Reconstr Surg. 2000;16:119-125.
24. Smits VA, Klompmaker R, Vallenius T, Rijksen G, Makela TP, Medema RH p21 inhibits thr 161 phosphorylation of cdc2 to enforce the G2 DNA damage checkpoint. J. Biol. Chem. 30638-30643.
25. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998;282:1497-1501.
26. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
27. Kang SC, Chung H, Yoo YD, Lee JG, Choi YI, Yu YS. Mechanism of growth inhibitory effect of mitomycin-C on cultured human retinal pigment epithelial cells: apoptosis and cell cycle arrest. Current Eye Res. 2001;22:174-181.
28. Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem. 2002;277:40513-40519.
29. Marxs SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
30. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645.
31. Sartorelli AC. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988;48:775-778.
32. Khaw PT, Doyle JW, Sherwood MB, Griersoin I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures, to fluorouracil and mitomycin C. Arch Ophthalmol. 1993;111:263-267.
33. Erard A-C, Monnier P, Spiliopoulos A, Nicod L. Mitomycin C for control of recurrent bronchial stenosis: a case report. Chest. 2001;120: 2103-2105.
34. Franzco MD, Maini R, Tole D. Use of mitomycin C in the treatment of corneal conjuctival intraepithelial neoplasia. Clin Exp Ophthalmol. 2002; 30:94-98.
35. Chen C, Louis D, Dodd T, Muecke J. Mitomycin C as an adjunct in the treatment of localized ocular surface squamous neoplasia. Br J Ophthalmol. 2004;88:17-18.
36. Prasad M, Ward RF, April MM, Bent JP, Froehlich P. Topical mitomycin C as an adjunct to choanal atresia repair. Arch Otololaryngol. 2002;128: 398-400.
37. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G, Bonatti JO. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg. 2004;77:1580-1585.
38. Bennet MR, Lindner V, DeBois D, Reidy MA, Schwartz SM. Effect of phosphothiorated oligonucleotides on neointima formation in the rat carotid artery: dissecting the mechanism of action. Arterioscl Thromb Vasc Biol. 1997;17:2326-2332.
39. Strauss BH, Wilson RA, Houten RV, Suylen RV, Murphy ES, Escaned J, Verdouw PD, Serruys PW, van der Giessen WJ. Late effects of locally delivered mitomycin C on formation of neointima and on vasomotor response to acetylcholine. Coron Art Dis. 1994;5:633-641.